PEDIATRICS Vol. 57 No. 4 April 1976, pp. 441-442
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chase, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chase, H. P.

Fatty acids, prostaglandins, and cystic fibrosis

H. Peter Chase M.D.1

1 University of Colorado, Medical Center, Department of Pediatrics, 4200 East Ninth Avenue, Denver, Colorado 80220

The papers by Elliott1 and by Campbell et al.2 in this issue of Pediatrics suggest a new approach toward etiology, pathophysiology, and therapy in patients with cystic fibrosis (CF). As in Elliott's original report of the effects of intravenous fatty acid therapy for CF,3 the patients in the present report fared remarkably well, particularly in regard to weight gain. As only 18 calories/kg of body weight were infused every three weeks, it is unlikely the increments in weight were due to calories. As noted in both papers1,2 previous investigators have also described essential fatty acid (EFA) deficiency in CF, and every experimental animal in which EFA deficiency has been produced has shown growth failure.